上海昊海生物科技股份有限公司（06826）于2026年7月20日公告披露，当日在香港联交所场内回购H股共161,000股，占当日已发行股份总数的约0.0716%。最高回购价为每股16.85港元，最低回购价为每股16.14港元，总耗资约263.96万港元。该部分回购股份尚未注销，暂时仍计入公司已发行股本。
本次回购基于股东大会于2026年5月29日通过的购回授权，授权股份数为3,478,034股。截至目前，公司累计回购161,000股，占购回授权决议通过当日已发行股份（不包括库存股份）数目的约0.4629%。
截至公告日，公司H股已发行股份数为34,780,340股，A股已发行股份数为190,203,760股，合计普通股224,984,100股。公司在公告中确认，所有回购行动均符合香港联合交易所上市规则及相关法律法规要求。
公告由公司董事兼联席公司秘书田敏签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.